Skip to main content
. 2010 Sep 24;4:221–229. doi: 10.2147/dddt.s3143

Table 1.

Phase III trials of azacitidine as a single agent

Study CALGB 9221 No. (%) Updated CALGB No. (%) AZA-001 No. (%)
No. patients 99 99 179
CR 7 (7) 10 (10) 30 (17)
PR 16 (16) 1 (1) 21 (12)
HI 37 (37) 36 (36) 87 (49)
OR 60 (60) 47 (47) 138 (78)

Abbreviations: CR, complete remission; PR, partial remission; HI, hematological improvement; OR, overall response.